Can I read Troglitazone (Rezulin) and hepatic injury on EtoBox?

Troglitazone (Rezulin) and hepatic injury by Gerald A. Faich; Richard H. Moseley is a Medicine article available to read on EtoBox.

What is Troglitazone (Rezulin) and hepatic injury about?

## Abstract ## Purpose Analyze US rates of reported severe liver disease for the oral hypoglycemic agent troglitazone from March 1997 through February 2000 and the possible effects of publicity on reporting. ## Methods The number of troglitazone reports with liver failure and or hospitalization with jaundice or hyperbilirubinemia, made to the FDA and/or Parke‐Davis are used as numerators. The denominators are numbers of patients and person‐time estimates of exposure. Additionally, the amount of publicity about troglitazone during its marketing is quantified. ## Results Approximately 1.92 million patients were treated with troglitazone from March 1997 through the end of February 2000 resulting in 1.6 million person‐years of exposure. Reports of 83 cases of liver failure associated with troglitazone were received (1 in 23 000 patients or 1 in 20 000 person‐years). Of the 83 cases, only 49 (59%) were classified by a hepatologist to be ‘possibly’ or ‘probably’ attributed to troglitazone. For the first, second, and third years of marketing, rates of reported hepatic failure per 100 000 person years exposure to troglitazone were 8.3, 5.3, and 2.7 respectively. Rates of reported liver dis

Who reads Troglitazone (Rezulin) and hepatic injury?

Author

Gerald A. Faich; Richard H. Moseley

Publisher

John Wiley and Sons; Wiley (John Wiley & Sons); John Wiley & Sons Inc.; Wiley (ISSN 1053-8569)

Published

2001

Language

EN

Field

Medicine (Health Sciences)